MAGEC2 and bladder transitional cell carcinoma: In a recent study, two CTAs, PRAME and CT10, were found to be expressed in 15% and 21% of bladder urothelial carcinomas, and these tumors had a poorer prognosis, with CT10-positive patients experiencing worse disease-specific survival [66].